Posted by Michael Wonder on 26 Feb 2021
Thousands of breast cancer patients to have routine access to NICE-approved drug combination
26 February 2021 - Another potentially life-extending drug combination for some people with advanced breast cancer will now be available for routine use after draft guidance from NICE today recommended ribociclib (Kisqali, Novartis) is taken out of the Cancer Drugs Fund.
The draft guidance recommends ribociclib plus fulvestrant as an option for treating a type of breast cancer called hormone receptor-positive, human epidermal growth factor receptor 2 negative, locally advanced or metastatic breast cancer.
